NCT05506449终止不适用
Early Impella® Support in Patients With ST-Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock: The RECOVER IV Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Abiomed Inc.
- 入组人数
- 4
- 试验地点
- 9
- 主要终点
- All-Cause Mortality
研究概览
简要总结
The purpose of this study is to assess whether hemodynamic support with an Impella-based treatment strategy initiated prior to percutaneous coronary intervention (PCI) in patients with ST-Segment Elevation Myocardial Infarction (STEMI)-Cardiogenic Shock (CS) improves survival and functional outcomes compared to a non-Impella-based treatment strategy.
详细描述
To demonstrate that hemodynamic support with an Impella-based treatment strategy initiated prior to PCI, when compared with a non-Impella-based standard of care treatment strategy reduces all-cause mortality at 30 days in patients with STEMI-CS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cardiogenic shock with onset ≤12 hours after STEMI and prior to index PCI, as defined by having both the following:
- •Persistent SBP <90 mmHg for ≥30 minutes despite fluid resuscitation or pressors/inotropes required to maintain SBP ≥90 mmHg and
- •Signs of impaired organ perfusion (cool extremities and/or altered mental status)
- •One of the following must be present on a standard 12-lead electrocardiogram (ECG):
- •ST-segment elevation (≥2 mm elevation of ST-segments in ≥2 contiguous leads without left bundle branch block) or
- •Anterior (V1-V4) ST-segment depression ≥2 mm in ≥2 contiguous leads consistent with a possible posterior infarction AND coronary angiogram prior to randomization showing acute total or subtotal occlusion of the proximal circumflex artery or
- •aVR ST-segment elevation ≥2 mm without anterior ST-segment elevation AND coronary angiogram prior to randomization confirming left main culprit lesion
- •NOTE: Patients with isolated RV infarction are excluded from this Protocol. If a patient qualifies with cardiogenic shock with only inferior ST-segment elevation, pre-randomization assessment of LV function must be obtained with either point of care echocardiography or contrast left ventriculography to demonstrate a LVEF ≤40% for the patient to be eligible for randomization.
- •Intended emergent PCI to treat the STEMI
- •Subject is able to and agrees to provide written informed consent. If the subject is unable to be consented because of their extreme illness and a legally authorized representative (LAR) is present, the LAR must agree and provide written informed consent. If the subject is unable to provide consent because of their extreme illness and an LAR is not present, the patient may be randomized under Exception from Informed Consent (EFIC) Guidance
排除标准
- •High suspicion for isolated right ventricular infarct confirmed with ECG lead V4R
- •Cardiogenic shock with either of the following:
- •High-grade atrioventricular block (heart rate (HR) <50 bpm)
- •NOTE: If patient is paced, via temporary or permanent pacemaker, and still in shock, they are still eligible
- •Isolated narrow complex supraventricular tachycardia with ventricular response >170 bpm or ventricular tachyarrhythmia with ventricular response >150 bpm
- •Known mechanical complications of acute myocardial infarction (AMI) that may cause cardiogenic shock such as free wall rupture, cardiac tamponade, ventricular septal defect or papillary muscle rupture with acute mitral regurgitation
- •Left ventricular function (LVEF >40%) on echocardiography or LV-gram (if performed) indicating shock due to another cause (e.g., RV infarction as the principal cause of shock, hypovolemia, sepsis or high cardiac output shock)
- •Severe bilateral peripheral arterial disease precluding femoral Impella CP insertion (femoral angiogram required) NOTE: Impella insertion via a non-femoral arterial route is not permitted in this Protocol.
- •IABP, Impella or other mechanical circulatory support already in place for present indication (pre-randomization)
- •Known end-stage renal disease, receiving dialysis
- •Severe aortic stenosis, or moderate or worse aortic regurgitation or prior self-expanding transcatheter aortic valve replacement (TAVR), or surgically placed mechanical valve, if known
- •Acute or chronic aortic dissection, if known
- •Large or mobile LV thrombus, if known
- •Prior PCI for the present infarction
- •Prior PCI or coronary artery bypass graft (CABG) within 1 year, if known
- •Ongoing cardiopulmonary resuscitation (CPR)
- •Not obeying verbal commands after preadmission or in-hospital cardiac arrest
- •NOTE: (i) A positive and appropriate response to commands must be repeatable on at least two (2) instances to rule out reflex response to voice (ii) Intubated subjects may be enrolled if:
- •They did not have a cardiac arrest and were following verbal commands prior to intubation or
- •They are clearly following verbal commands after intubation
- •Prior stroke with permanent, significant neurological defect
- •Prior intracranial hemorrhage or known intracerebral mass, aneurysm or fistula
- •Acute or suspected stroke prior to randomization
- •Active infection requiring oral or intravenous antibiotics
- •Prior heparin-induced thrombocytopenia, if known
- •Other severe, concomitant disease with limited life expectancy <1 year (other than cardiogenic shock)
- •Pregnancy, known or suspected
- •Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached its primary endpoint or any cardiogenic shock trial other than a registry
- •If known, subject has previously been symptomatic with or hospitalized for COVID-19 unless he/she has been discharged (if hospitalized) and asymptomatic for ≥4 weeks and has returned to his/her prior baseline (pre-COVID) clinical condition
- •Subject has other medical, social or psychological conditions that, in the opinion of the Investigator, compromises the subject's ability to comply with study procedures (e.g., dementia, severe alcohol or substance abuse)
- •Patient belongs to a vulnerable population [Vulnerable patient populations may include individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention]
- •Patient is wearing a bracelet or other item indicating their wishes to decline participation in the study
结局指标
主要结局
All-Cause Mortality
时间窗: 30 Days
次要结局
- Days Alive Out-of-Hospital(6 Months)
- Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)(30 Days)
- Mean Change in Health-Related Quality of Life, as measured by Kansas City Cardiomyopathy Questionnaire(1 Year)
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
不适用
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU TrialST Elevation (STEMI) Myocardial Infarction of Anterior WallNCT03947619Abiomed Inc.527
Unknown
不适用
The Use of Impella RP Support System in Patients With Right Heart FailureRight Heart FailureNCT01777607Abiomed Inc.30
已完成
不适用
Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia AblationVentricular TachycardiaNCT01294267Vivek Reddy20
已完成
不适用
MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI TrialST-elevation Myocardial InfarctionMultivessel Coronary DiseaseNCT03135275University of Zurich840
已完成
不适用
National Cardiogenic Shock InitiativeSTEMI - ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation MIHeart AttackAcute Myocardial InfarctionCardiogenic ShockNCT03677180Henry Ford Health System406